Treatment
Ustekinumab clinical trials
We’re tracking 29 recruiting studies that include Ustekinumab, each written for real people, not researchers, below.
Recruiting studies
- NCT06520397RecruitingPhase 4
Combination therapy vs. higher dose ustekinumab for Crohn's
This trial tests whether a combination of two drugs (upadacitinib and ustekinumab) works better than a higher dose of ustekinumab alone for people with active Crohn's disease that hasn't responded well to previous treatments.
Guangzhou, GuangdongAges 18–70 - NCT06997055Recruiting
Study of Steqeyma® biosimilar in Crohn's and psoriasis
This study follows people with Crohn's disease or plaque psoriasis who are switching from the reference Ustekinumab to a biosimilar (Steqeyma®). It aims to see how well the biosimilar works in real-world settings.
AmiensAges 18 years+ - NCT07303686RecruitingPhase 4
Reducing Stelara dose in Crohn's and colitis remission
This trial studies whether people with Crohn's disease or ulcerative colitis who are in deep remission can safely reduce their dose of ustekinumab (Stelara) without the disease coming back. It aims to reduce medication burden while keeping patients well.
Montreal, QuebecAges 18 years+ - NCT07116967RecruitingPhase 3
Long-term safety of two psoriasis drugs in people with heart risk
This study compares two medications for psoriasis (deucravacitinib and ustekinumab) over a long period. It's designed for people with moderate-to-severe psoriasis who also have certain risk factors for heart disease, like high blood pressure or diabetes.
Birmingham, AlabamaAges 40 years+ - NCT06045754RecruitingPhase 4
Study of vedolizumab with other drugs for Crohn's disease
This trial tests whether combining vedolizumab with adalimumab or ustekinumab helps people with moderate to severe Crohn's disease who haven't responded to other treatments. It aims to find better ways to manage symptoms and improve quality of life.
Dothan, AlabamaAges 18–70 - NCT07529236Recruiting
How Children's Bowel Disease Responds After Switching IBD Medications
This study follows children who had to stop one type of IBD medicine (anti-TNFα) because it caused a skin condition called psoriasis, and were switched to a different medicine called ustekinumab. Researchers want to see how well their bowel disease is controlled with the new treatment.
Nice, FranceAges 6–17 - NCT03167437RecruitingPhase 1/Phase 2
Vorinostat for uncontrolled Crohn’s or ulcerative colitis
This early-phase study tests vorinostat to reduce gut inflammation in people with moderate-to-severe Crohn’s disease, ulcerative colitis, or certain colitis patterns linked to chronic granulomatous disease (CGD). It also looks at whether the study’s consent process is clear and understood before starting treatment.
Bethesda, MarylandAges 18–65 - NCT04372108Recruiting
Long-term safety study for ustekinumab vs other biologics
This study follows adults with Crohn’s disease or ulcerative colitis to compare the long-term safety of ustekinumab against other biologic medicines. It may help show how safe these treatments are over time, using medical records.
Portsmouth, VirginiaAges 18 years+ - NCT05387031Recruiting
Ustekinumab for painful Crohn’s bowel narrowing
This trial tests ustekinumab, a medicine that calms immune inflammation, to see if it can improve symptoms in people with Crohn’s disease that causes bowel narrowing. It may help if your Crohn’s symptoms come from strictures (narrowed areas) seen on scans or endoscopy.
Beijing, Beijing MunicipalityAges 18–65 - NCT05725876RecruitingPhase 1
Imaging ustekinumab medicine movement in Crohn’s and psoriasis
This Phase 1 study uses a special camera to track how ustekinumab (a common biologic medicine) spreads in inflamed tissue. It aims to help researchers understand where the drug goes in Crohn’s disease and psoriasis, especially when standard treatments haven’t worked.
GroningenAges 18 years+ - NCT06453317RecruitingPhase 2
Comparing UC treatments: infliximab vs ustekinumab vs both
This study compares an existing UC medication (infliximab) with a newer one (ustekinumab) and a combination of both. The goal is to see which works best for moderate to severe UC when other treatments have failed.
LodzAges 18–64 - NCT06807593RecruitingPhase 2
Treating ICI-related diarrhea or colitis with ustekinumab
This trial tests if ustekinumab can help cancer patients who have diarrhea or colitis caused by immune checkpoint inhibitors. It may be an option if standard treatments haven't worked or aren't suitable.
Houston, TexasAges 18 years+ - NCT06912815Recruiting
Ustekinumab and nutrition before Crohn's surgery
This trial tests if combining a drug called ustekinumab with a special liquid diet (semi-exclusive enteral nutrition) is as effective as using only the liquid diet to improve outcomes before Crohn's surgery.
Guangzhou, GuangdongAges 18–65 - NCT07444060Recruiting
Guselkumab vs Ustekinumab for stricturing Crohn's disease
This study compares two medicines, Guselkumab and Ustekinumab, for people with Crohn's disease that causes narrowing (strictures) in the bowel. It aims to find which works better to improve symptoms and avoid the need for more procedures.
Hangzhou, ZhejiangAges 18–80 - NCT07746583Recruiting
Switching from ustekinumab to guselkumab for psoriasis
This study is testing a medicine called guselkumab (Tremfya) for people with psoriasis who are already taking another biologic medicine, ustekinumab, but need to switch. The goal is to see how well guselkumab works in real-world use.
BudapestAges 18 years+ - NCT05186623Recruiting
Personalized prediction for ulcerative colitis treatment response
This study builds a prediction model to estimate how people with ulcerative colitis may respond to certain medicines. It may help doctors choose the most effective treatment sooner.
SeoulAges 18–79 - NCT05270733RecruitingPhase 4
Predicting psoriasis response using advanced skin-cell testing
This study looks at skin cells at the single-cell level to predict which psoriasis treatments will work best for you. It may help doctors personalize treatment choices for plaque psoriasis.
Cleveland, OhioAges 18–89 - NCT05928039RecruitingPhase 4
Choosing the best first biologic for Crohn’s in the ileum
This Phase 4 trial tests which type of biologic medicine works best as the first treatment for people with moderate-to-severe Crohn’s that mainly affects the ileum. It may help you and your care team choose a more effective first option, based on which strategy leads to better control of symptoms and intestinal inflammation.
Calgary, AlbertaAges 18 years+ - NCT07694674Recruiting
Comparing Biologic Drugs to Prevent Crohn's Return After Surgery
This trial compares different biologic medications to see which best prevents Crohn's disease from coming back after intestinal surgery. It may help you if you have had surgery for Crohn's and are starting a biologic drug soon after.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT07245394Recruiting
Switching to guselkumab for inflammatory bowel disease after ustekinumab
This trial tests whether switching from the drug ustekinumab to another drug called guselkumab can help people with active inflammatory bowel disease (IBD) who didn't get enough benefit from ustekinumab. It focuses on people with Crohn's disease or ulcerative colitis who still have signs of inflammation in their gut.
Calgary, AlbertaAges 18 years+ - NCT07138898RecruitingPhase 2
Managing immune medications for shoulder replacement in rheumatology patients
This trial tests two ways of managing your immunosuppressant medication around the time of shoulder replacement surgery. The goal is to see if one approach leads to fewer infections while still controlling your rheumatic disease.
New York, New YorkAges 18 years+ - NCT06523647Recruiting
Effectiveness of Ustekinumab for Crohn's Disease
This study looks at how well Ustekinumab (Stelara) works for Crohn's disease in people who started the medication in 2024. Researchers want to understand its real-world benefits and safety.
AktobeAges 18 years+ - NCT06691061Recruiting
Comparing advanced treatments for ulcerative colitis after anti-TNF therapy
This trial compares three types of medications (vedolizumab, ustekinumab, and JAK inhibitors) in people with ulcerative colitis who have already tried an anti-TNF drug but still have active disease. The goal is to see which treatment works best as a second option.
Mialn, ItalyAges 18 years+ - NCT06802887Recruiting
Long-term study of ustekinumab for Crohn's and colitis
This study follows patients with Crohn's disease or ulcerative colitis who started taking ustekinumab between February 2019 and March 2021, to see how well it works over time.
Bologna, BolognaAges 18 years+
What Ustekinumab is being studied for
Conditions with recruiting Ustekinumab studies.
Common questions
- Are there clinical trials studying Ustekinumab?
- Yes. Clin2 currently lists 29 recruiting studies that include Ustekinumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Ustekinumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Ustekinumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Ustekinumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.